Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017634 | 0.83 | SMN1; SMN2 (0.55) | KCNA5GAASMN1; SMN2ACP3ALDH1A1 | |
| SCHEMBL1921464 | 0.80 | CYP19A1 (0.46) | IDO1TDO2CYP19A1GAASMN1; SMN2 | |
| SCHEMBL11629773 | 0.79 | SMN1; SMN2 (0.62) | KCNA5KCND3CYP19A1GAASMN1; SMN2 | |
| SCHEMBL14685882 | 0.78 | CYP19A1 (0.46) | KCNA5IDO1TDO2CYP19A1GAA | |
| SCHEMBL8545947 | 0.77 | HPGD (0.37) | KCNA5CYP19A1GAAROCK2SMN1; SMN2 | |
| SCHEMBL424623 | 0.75 | ACP3 (0.50) | IDO1TDO2ACP3ALDH1A1ADRB1 | |
| SCHEMBL10967991 | 0.72 | SMN1; SMN2 (0.53) | KCNA5IDO1TDO2KCND3CYP19A1 | |
| SCHEMBL4857317 | 0.71 | L3MBTL1 (0.39) | IDO1TDO2GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL4705649 | 0.71 | KCNA5 (0.48) | KCNA5KCND3GAASMN1; SMN2ACP3 | |
| SCHEMBL8690340 | 0.70 | SMN1; SMN2 (0.55) | KCNA5GAASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199544-A1 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
| US-20030199542-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199542-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | KCNA5 4619/4885IDO1 4475/4885TDO2 4369/4885 |
| US-20030199544-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | KCNA5 4619/4885IDO1 4475/4885TDO2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.